Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Executive Summary

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Advertisement

Related Content

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
Pieris And Seattle Strike IO Deal
Theravance Banks $100m As J&J Bets Big On IBD Drug
AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies
Puma's Nerlynx Scores Broad Label Across Adjuvant Breast Cancer Subgroups

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel